Evaluation of the safety of cefepime prolonged infusions in pediatric patients with cystic fibrosis.

Objective: Pediatric cystic fibrosis (CF) patients possess unique pharmacokinetics and may benefit from prolonged beta-lactam infusions to optimize pharmacodynamics. This study compared adverse drug event (ADE) rates with cefepime prolonged (PI) and standard infusions (SI).

Methods: This retrospective study included pediatric patients treated with cefepime for CF exacerbations between 2009 and 2019.